Welcome to Markets Desk, your midday read on what's moving markets and why.
Bank of America nudged its price target on Supermicro to thirty-nine dollars from thirty-eight, but held its Underperform rating — a telling combination. The AI server maker posted a staggering two hundred ninety-eight percent revenue surge, yet BofA's concern sits squarely on margin compression and cash flow durability as the AI buildout matures.
Staying in the AI space, a quieter political force may be reshaping the sector's growth trajectory. Voters across the country backed anti-data center candidates and ballot measures on Election Day, signaling real grassroots resistance to the infrastructure AI demands. If that sentiment hardens into policy, the capital expenditure runway Wall Street has been pricing in gets considerably shorter.
On the earnings front, Cytokinetics delivered a striking quarter, reporting total revenues of forty-seven point six million dollars against just one point nine million in the same period last year. That surge is almost entirely driven by MYQORZO, its newly commercialized heart drug, which alone generated forty-four point five million in net product revenue — a genuine commercial launch inflection.
That's the tape. Markets Desk, signing off the floor.
